一项评估efinopegdutide治疗非酒精性脂肪性肝病疗效与安全性的IIa期活性对照研究
这项IIa期随机、活性对照、平行组、开放标签研究纳入145例非酒精性脂肪性肝病患者,按1:1随机接受efinopegdutide 10 mg或司美格鲁肽1 mg每周皮下注射24周。第24周时efinopegdutide组肝脏脂肪含量相对降低72.7%,显著大于司美格鲁肽组的42.3%(p<0.001)。
要点
- efinopegdutide 10 mg每周一次治疗24周,肝脏脂肪含量相对降低72.7%,显著大于司美格鲁肽1 mg的42.3%。
- 两组体重相对降低分别为efinopegdutide 8.5%与司美格鲁肽7.1%,差异无统计学意义(p=0.085)。
- efinopegdutide组不良事件和药物相关不良事件发生率略高于司美格鲁肽组,主要与胃肠道不良事件不平衡有关。
核心结论
- 在非酒精性脂肪性肝病患者中,每周一次efinopegdutide 10 mg治疗导致的肝脏脂肪含量降低显著大于每周一次司美格鲁肽1 mg。
- 作者认为efinopegdutide可能是非酒精性脂肪性肝炎的有效治疗。
研究设计与样本
- IIa期、随机、活性对照、平行组、开放标签研究。
- 筛查时肝脏脂肪含量≥10%的参与者按1:1随机分配至efinopegdutide 10 mg组(n=72)或司美格鲁肽1 mg组(n=73),两组均每周皮下注射一次,共24周。
- 按合并2型糖尿病诊断进行分层,两种药物均在8周内滴定至目标剂量。
- 主要疗效终点为治疗24周后肝脏脂肪含量相对基线的百分比降低。
主要发现
- 共145例随机参与者,33.1%患有2型糖尿病;基线平均BMI为34.3 kg/m2,平均肝脏脂肪含量为20.3%。
- 第24周肝脏脂肪含量相对基线的最小二乘均值相对降低:efinopegdutide组为72.7%(90% CI 66.8-78.7),司美格鲁肽组为42.3%(90% CI 36.5-48.1),efinopegdutide组显著更大(p<0.001)。
- 第24周体重相对基线的最小二乘均值百分比降低:efinopegdutide组为8.5%,司美格鲁肽组为7.1%(p=0.085)。
- efinopegdutide组不良事件和药物相关不良事件发生率略高于司美格鲁肽组,主要与胃肠道不良事件不平衡有关。
关键数值与推荐
- efinopegdutide 10 mg每周一次与司美格鲁肽1 mg每周一次相比,第24周肝脏脂肪含量相对降低分别为72.7%与42.3%(p<0.001)。
- 体重相对降低分别为efinopegdutide 8.5%与司美格鲁肽7.1%(p=0.085)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: This study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: This was a phase IIa, randomized, active-comparator-controlled, parallel-group, open-label study. A magnetic resonance imaging-estimated proton density fat fraction assessment was performed to determine LFC at screening and Week 24. Participants with an LFC of ≥10% at screening were randomized 1:1 to efinopegdutide 10 mg or semaglutide 1 mg, both administered subcutaneously once weekly for 24 weeks. Participants were stratified according to the concurrent diagnosis of type 2 diabetes mellitus (T2DM). Both drugs were titrated to the target dose over an 8-week time period. The primary efficacy endpoint was relative reduction from baseline in LFC (%) after 24 weeks of treatment. RESULTS: Among 145 randomized participants (efinopegdutide n = 72, semaglutide n = 73), 33.1% had T2DM. At baseline, mean BMI was 34.3 kg/m2 and mean LFC was 20.3%. The least squares (LS) mean relative reduction from baseline in LFC at Week 24 was significantly (p <0.001) greater with efinopegdutide (72.7% [90% CI 66.8-78.7]) than with semaglutide (42.3% [90% CI 36.5-48.1]). Both treatment groups had an LS mean percent reduction from baseline in body weight at Week 24 (efinopegdutide 8.5% vs. semaglutide 7.1%; p = 0.085). Slightly higher incidences of adverse events and drug-related adverse events were observed in the efinopegdutide group compared with the semaglutide group, primarily related to an imbalance in gastrointestinal adverse events. CONCLUSIONS: In patients with NAFLD, treatment with efinopegdutide 10 mg weekly led to a significantly greater reduction in LFC than semaglutide 1 mg weekly. CLINICAL TRIAL NUMBER: EudraCT: 2020-005136-30; NCT: 04944992. IMPACT AND IMPLICATIONS: Currently, there are no approved therapies for non-alcoholic steatohepatitis (NASH). The weight loss associated with glucagon-like peptide-1 (GLP-1) receptor agonists has been shown to decrease hepatic inflammation in patients with NASH. In addition to reducing liver fat content (LFC) indirectly through weight loss, glucagon receptor agonism may also reduce LFC by acting on the liver directly to stimulate fatty acid oxidation and reduce lipogenesis. This study demonstrated that treatment of patients with non-alcoholic fatty liver disease with the GLP-1/glucagon receptor co-agonist efinopegdutide (10 mg weekly) led to a significantly greater reduction in LFC compared to treatment with the GLP-1 receptor agonist semaglutide (1 mg weekly), suggesting that efinopegdutide may be an effective treatment for NASH.
引用
- Romero-Gómez M, Lawitz E, Shankar RR, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023. PMID: 37355043. doi:10.1016/j.jhep.2023.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。